呼出气一氧化氮在哮喘中的临床意义

doi:10.3877/cma.j.issn.1674-6902.2020.03.002

目的

哮喘以慢性气道炎性反应为特征，主要涉及嗜酸性粒细胞的募集和活化。呼出气一氧化氮(fractional exhaled nitric oxide, FeNO)是气道炎症的一个非侵入性标志物。本文探讨了FeNO在哮喘中的临床意义。

方法

我们评估了94例哮喘患者治疗前后的FeNO和肺功能参数及哮喘控制检测(asthma control test, ACT)评分，其中完成1个月随访的有75例，完成3个月随访的有73例，分析了我院哮喘患者控制水平的一些相关因素。

结果

发现诊断时的FEV1%在预测哮喘控制时最具优势，哮喘患者根据ACT评分划分的不同控制状态的FeNO和肺功能参数无明显差异。FeNO和肺功能参数，ACT评分及血IgE，血嗜酸性粒细胞计数之间无明显相关性。FEV1%与ACT评分之前存在正相关(r＝0.04184，P＝0.0492)。无过敏性鼻炎(allergic rhinitis, AR)组，FeNO和ACT评分之间存在负相关(r＝0.2015，P＝0.0128)。3个月治疗后FeNO和ACT评分之间仍无明显相关性。

结论

哮喘患者治疗前后的FeNO可以评估患者的治疗效果，而FeNO并不能预测哮喘的控制状态及恶化风险，FEV1%在预测哮喘控制方面具有临床意义。

关键词: 支气管哮喘, 呼出气一氧化氮, 肺功能, 哮喘控制检测评分, 临床意义

Objective

Asthma is characterized by chronic airway inflammatory responses, mainly involving the recruitment and activation of eosinophils. Exhaled nitric oxide (FeNO) is a non-invasive marker of airway inflammation. The article aims to explore the clinical role of FeNO in asthma patients.

Methods

We evaluated the FeNO, the pulmonary function parameters and the asthmatic control test (ACT) scores of 94 asthma patients before and after treatment. Among them, 75 patients completed the follow-up visits for one month and 73 patients completed the follow-up visits for three months. We analyzed some related factors of the control level of asthma patients in our hospital.

Results

The percentage of forced expiratory volume in one second (FEV1%) at diagnosis had the most advantage in predicting asthma control, and there was no significant difference in FeNO and pulmonary function parameters of asthma patients according to the ACT scores. There was no significant correlation between FeNO and pulmonary function parameters, ACT scores, IgE and eosinophil count. There was a positive correlation between FEV1% and ACT scores (r=0.04184, P=0.0492). There was a negative correlation between FeNO and ACT scores in the allergic rhinitis (AR) group (r=0.2015, P=0.0128). There was no significant correlation between FeNO and ACT scores after 3 months of treatment.

Conclusion

FeNO before and after treatment can evaluate the therapeutic effect of the patients with asthma, but FeNO cannot predict the control status and the risk of asthma deterioration. FEV1% has more advantages in predicting asthma control.

Key words: Bronchial asthma, Exhaled nitric oxide, Lung functions, Asthmatic control test scores, Clinical significance

图1 A：FeNO，FEV1%，MEF25%+MEF50%的ROC曲线；B：FeNO+FEV1%, FeNO+FEV1%+MEF25%+MEF50%，FEV1%+MEF25%+MEF50%，FeNO+MEF25%+MEF50%的联合ROC曲线

表1 入组时的哮喘患者不同指标ROC曲线

变　量	AUC	P值	95%CI
FeNO	0.474	0.695	0.337～0.611
FEV1%	0.609	0.098	0.479～0.739
MEF25%+MEF50%	0.598	0.138	0.473～0.724
FeNO+FEV1%	0.596	0.145	0.466～0.726
FeNO+FEV1%+MEF25%+MEF50%	0.602	0.123	0.477～0.727
FEV1%+MEF25%+MEF50%	0.594	0.156	0.468～0.720
FeNO+MEF25%+MEF50%	0.606	0.108	0.482～0.730

表1 入组时的哮喘患者不同指标ROC曲线

变　量	AUC	P值	95%CI
FeNO	0.474	0.695	0.337～0.611
FEV1%	0.609	0.098	0.479～0.739
MEF25%+MEF50%	0.598	0.138	0.473～0.724
FeNO+FEV1%	0.596	0.145	0.466～0.726
FeNO+FEV1%+MEF25%+MEF50%	0.602	0.123	0.477～0.727
FEV1%+MEF25%+MEF50%	0.594	0.156	0.468～0.720
FeNO+MEF25%+MEF50%	0.606	0.108	0.482～0.730

表2 不同控制状态的哮喘患者入组时FeNO和肺功能参数的比较

组　别		例数	FeNO	FEV1%	FEV₁/FVC%	MEF25%	MEF50%
未控制组ACT		58	64.95±52.20	88.46±21.27	75.16±14.79	64.17±36.89	70.35±29.24
控制组ACT		36	65.94±52.59	93.69±18.70	78.37±13.18	78.01±42.75	79.35±24.22
	P值		0.9332	0.2330	0.2952	0.1025	0.1253

表2 不同控制状态的哮喘患者入组时FeNO和肺功能参数的比较

组　别		例数	FeNO	FEV1%	FEV₁/FVC%	MEF25%	MEF50%
未控制组ACT		58	64.95±52.20	88.46±21.27	75.16±14.79	64.17±36.89	70.35±29.24
控制组ACT		36	65.94±52.59	93.69±18.70	78.37±13.18	78.01±42.75	79.35±24.22
	P值		0.9332	0.2330	0.2952	0.1025	0.1253

图2 A：入组时的哮喘患者FeNO和ACT的相关性分析；B：入组时的哮喘患者FeNO和IgE的相关性分析；C：入组时的哮喘患者FeNO和嗜酸性粒细胞计数的相关性分析；D：入组时的哮喘患者FeNO和FEV%的相关性分析

图3 A：所有入组时的哮喘患者的ACT和FEV1%的相关性分析；B：入组时的不合并过敏性鼻炎的哮喘患者ACT和FeNO的相关性分析

图4 A：入组时的哮喘患者和完成3个月随访的哮喘患者FeNO的水平比较；B：入组时的哮喘患者和完成1个月及3个月随访的哮喘患者ACT的水平比较

图5 完成3个月随访的哮喘患者ACT与FeNO的相关性分析

1	Bateman ED, Hurd SS, Barnes PJ, et al. Global strategy for asthma management and prevention: GINA executive summary[J]. Eur Respir J, 2008, 31(1): 143-178.
2	Taylor DR, Bateman ED, Boulet LP, et al. A new perspective on concepts of asthma severity and control[J]. Eur Respir J, 2008, 32(3): 545-554.
3	Bateman ED, Hurd SS, Barnes PJ, et al. Global strategy for asthma management and prevention: GINA executive summary[J]. Eur Respir J, 2008, 51(2): 0751387.
4	Alving K, Weitzberg E, Lundberg JM. Increased amount of nitric oxide in exhaled air of asthmatics[J]. Eur Respir J, 1993, 6(9): 1368-1370.
5	Sato S, Saito J, Sato Y, et al. Clinical usefulness of fractional exhaled nitric oxide for diagnosing prolonged cough[J]. Respir Med, 2008, 102(10): 1452-1459.
6	Kharitonov SA, Robbins RA, Yates D, et al. Acute and chronic effects of cigarette smoking on exhaled nitric oxide[J]. Am J Respir Crit Care Med, 1995，152(2): 609-612.
7	Smith AD, Cowan JO, Brassett KP, et al. Exhaled nitric oxide: a predictor of steroid response[J]. Am J Respir Crit Care Med, 2005, 15, 172(4): 453-459.
8	Porsbjerg C, Lund TK, Pedersen L, et al. Inflammatory subtypes in asthma are related to airway hyperresponsiveness to mannitol and exhaled NO[J]. J Asthma, 2009, 46(6): 606-612.
9	Schleich FN, Seidel L, Sele J, et al. Exhaled nitric oxide thresholds associated with a sputum eosinophil count >/＝3% in a cohort of unselected patients with asthma[J]. Thorax, 2010, 65(12): 1039-1044.
10	Bjerregaard A, Laing IA, Backer V, et al. Clinical characteristics of eosinophilic asthma exacerbations[J]. Respirology, 2017, 22(2): 295-300.
11	Michils A, Baldassarre S, Muylem AV. Exhaled nitric oxide and asthma control: a longitudinal study in unselected patients[J]. Eur Respir J, 2008, 31(3): 539-546.
12	Raed AD, Peter BB, Serpil CE, et al. An official ATS clinical practice guideline: interpretation of exhaled nitric oxide levels (FeNO) for clinical applications[J]. Am J Respir Crit Care Med, 2011, 184(5): 602-615.
13	Miller MR, Crapo R, Hankinson J, et al. General considerations for lung function testing[J]. Eur Respir J, 2005, 26(1): 153-161.
14	Zhou X, Ding FM, Lin JT, et al. Validity of asthma control test for asthma control assessment in Chinese primary care settings[J]. Chest, 2009, 135(4): 904-910.
15	Hoyte FCL, Gross LM, Katial RK. Exhaled Nitric Oxide: An Update[J]. Immunol Allergy Clin North Am, 2018, 38(4): 573-585.
16	Barnes PJ, Dweik RA, Gelb AF, et al. Exhaled nitric oxide in pulmonary diseases: a comprehensive review[J]. Chest, 2010, 138(3): 682-692.
17	Salviano L, Taglia-Ferre KD, Lisboa S, et al. Association between fraction of exhaled nitric oxide and spirometry data and clinical control of asthma in children and adolescents[J]. Rev Paul Pediatr, 2018, 36(1): 8.
18	Shirai T, Furuhashi K, Suda T, et al. Relationship of the asthma control test with pulmonary function and exhaled nitric oxide[J]. Ann Allergy Asthma Immunol, 2008, 101(6): 608-613.
19	Essat M, Harnan S, Gomersall T, et al. Fractional exhaled nitric oxide for the management of asthma in adults: a systematic review[J]. Eur Respir J, 2016, 47(3): 751-768.
20	Smith AD, Cowan JO, Brassett KP, et al. Use of exhaled nitric oxide measurements to guide treatment in chronic asthma[J]. N Engl J Med, 2005, 352(21): 2163-2173.
21	Shaw DE, Berry MA, Thomas M, et al. The use of exhaled nitric oxide to guide asthma management: a randomized controlled trial[J]. Am J Respir Crit Care Med, 2007, 176(3): 231-237.
22	Sato S, Saito J, Fukuhara A, et al. The clinical role of fractional exhaled nitric oxide in asthma control[J]. Ann Allergy Asthma Immunol, 2017, 119(6): 541-547.
23	Charles GI, Jason HT. Physiologic dysfunction of the asthmatic lung：what′s going on down there, anyway？[J]. Proc Am Thorac Soc, 2009, 6(3): 306-311.
24	Hirst SJ. Airway smooth muscle as a target in asthma[J]. Clin Exp Allergy, 2000, Suppl 1: 54-59.
25	Teague WG, Phillips BR, Fahy JV, et al. Baseline features of the severe asthma research program (SARP Ⅲ) cohort: Differences with age[J]. J Allergy Clin Immunol Pract, 2018, 6(2): 545-554 e4
26	Joseph DS, Reuben C, Keith P, et al. Is forced expiratory volume in one second the best measure of severity in childhood asthma？[J]. Am J Respir Crit Care Med, 2004, 169(7): 784-786.
27	Biju T, Oh MC, John CA Jr, et al. Concordance between bronchial hyperresponsiveness, fractional exhaled nitric oxide, and asthma control in children[J]. Pediatr Pulmonol, 2016, 51(10): 1004-1009.
28	Saito J, Gibeon D, Macedo P, et al. Domiciliary diurnal variation of exhaled nitric oxide fraction for asthma control[J]. Eur Respir J, 2014, 43(2): 474-484.
29	Garg Y, Kakria N, Katoch CDS, et al. Exhaled nitric oxide as a guiding tool for bronchial asthma: A randomised controlled trial[J]. Med J Armed Forces India, 2020, 76(1): 17-22.
30	Bernholm KF, Homoe AS, Meteran H, et al. FeNO-based asthma management results in faster improvement of airway hyperresponsiveness[J]. ERJ Open Res, 2018, 4(4): 00147-2017.

[1]	陈腊青, 林佳佳, 毛洪刚, 童冠海, 汪梦娜, 夏红波, 刘卓, 徐海霞, 赵玉华, 张传领. 血清细胞因子及呼出气一氧化氮在哮喘-慢性阻塞性肺疾病重叠综合征中的临床意义[J]. 中华危重症医学杂志(电子版), 2023, 16(04): 316-320.
[2]	纪文鑫, 王茂, 邱春丽, 李尚鹏, 代引海. 血清外泌体circ PVT1与circ 0014606在三阴性乳腺癌中的表达及临床意义[J]. 中华普外科手术学杂志(电子版), 2023, 17(03): 267-271.
[3]	王刚, 单伟根, 刘娟, 李长庆, 王新民. 常规治疗联合阿托伐他丁钙片对支气管扩张症临床分析[J]. 中华肺部疾病杂志(电子版), 2023, 16(04): 538-540.
[4]	刘佳铭, 孙晓容, 文健, 何晓丽, 任茂玲. 有氧运动对成人哮喘肺功能、生活质量以及哮喘控制影响的Meta分析[J]. 中华肺部疾病杂志(电子版), 2023, 16(04): 592-595.
[5]	谭玲芳, 周克兵. 基于生物信息学整合鉴定与支气管哮喘相关的潜在诊断生物标志物[J]. 中华肺部疾病杂志(电子版), 2023, 16(03): 329-334.
[6]	路东明, 陈建华, 艾月琴. 布地格福吸入气雾剂治疗支气管哮喘的临床分析[J]. 中华肺部疾病杂志(电子版), 2023, 16(03): 361-363.
[7]	刘康凯, 姚光辉. 补肺纳肾汤对COPD稳定期患者肺功能及外周血Treg、Th17细胞比率的影响[J]. 中华肺部疾病杂志(电子版), 2023, 16(03): 376-378.
[8]	孙臣忠, 韩碧芸, 陈虹, 陈英, 周军. 慢性阻塞性肺疾病免疫球蛋白亚型与肺功能相关性分析[J]. 中华肺部疾病杂志(电子版), 2023, 16(03): 403-405.
[9]	王小蓓, 秦雯, 符天选, 谭春苗. AECOPD睡眠障碍对肺功能炎性因子及焦虑抑郁状态的影响[J]. 中华肺部疾病杂志(电子版), 2023, 16(02): 260-262.
[10]	刘汶睿, 高丽娜, 于书娴, 周建刚. 支气管哮喘患者血清IL-27与IFN-γ及肺功能相关性分析[J]. 中华肺部疾病杂志(电子版), 2023, 16(02): 224-226.
[11]	宋昕, 耿涛, 刘长春. 老年下呼吸道感染者血清25-羟维生素D3水平与血清炎症因子水平的关系[J]. 中华肺部疾病杂志(电子版), 2023, 16(02): 215-217.
[12]	邹娟, 刘宇晴, 万园园. BiPAP无创呼吸机救治肺心病急性加重期疗效及对血清NT-proBNP、动脉血气指标和肺功能的影响[J]. 中华肺部疾病杂志(电子版), 2023, 16(01): 6-10.
[13]	胡守芳, 吴霞, 陈与知. 司美格鲁肽联合头孢哌酮钠舒巴坦治疗2型糖尿病并发肺炎的临床分析[J]. 中华肺部疾病杂志(电子版), 2023, 16(01): 43-46.
[14]	刘娜, 赵然然. 支气管哮喘微量元素水平与免疫功能的相关性分析[J]. 中华肺部疾病杂志(电子版), 2023, 16(01): 74-76.
[15]	蒋蔚茹, 徐三荣. 要努力弄清"慢性胃炎"的临床意义[J]. 中华诊断学电子杂志, 2023, 11(04): 266-270.

阅读次数

全文

摘要

选择文件类型/文献管理软件名称

选择包含的内容

Clinical significance of fractional exhaled nitric oxide in asthma patients

模态框（Modal）标题

选择文件类型/文献管理软件名称

选择包含的内容

Clinical significance of fractional exhaled nitric oxide in asthma patients